CN Patent

CN102480959A — 氢可酮的苯甲酸缀合物、苯甲酸衍生物缀合物和杂芳基羧酸缀合物及其前药、制备方法和用途

Assigned to Zevra Therapeutics Inc · Expires 2012-05-30 · 14y expired

What this patent protects

本申请提供组合物，所述组合物包含与氢可酮(4，5-α-环氧-3-甲氧基-17-甲基-吗啡烷-6-酮)化学缀合的芳基羧酸，从而形成氢可酮的新颖前药/组合物，所述芳基羧酸包括苯甲酸和杂芳基羧酸，所述组合物具有降低的氢可酮滥用潜在性。本申请还提供治疗患者的方法、药物试剂盒和合成本申请缀合物的方法。

USPTO Abstract

本申请提供组合物，所述组合物包含与氢可酮(4，5-α-环氧-3-甲氧基-17-甲基-吗啡烷-6-酮)化学缀合的芳基羧酸，从而形成氢可酮的新颖前药/组合物，所述芳基羧酸包括苯甲酸和杂芳基羧酸，所述组合物具有降低的氢可酮滥用潜在性。本申请还提供治疗患者的方法、药物试剂盒和合成本申请缀合物的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN102480959A
Jurisdiction
CN
Classification
—
Expires
2012-05-30
Drug substance claim
No
Drug product claim
No
Assignee
Zevra Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.